down arrow

Cullinan Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2300311063
USD
10.58
0.38 (3.73%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

10.0810.79

52 Week

5.6813.60
Valuation
Technical
Day's Volume

CASH

878.99 k

Shareholding (Mar 2025)

FII

17.51%

Held by 80 FIIs

DII

22.84%

Held by 30 DIIs

Promoter

38.05%

How big is Cullinan Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Cullinan Therapeutics, Inc. has a market capitalization of 491.00 million, with net sales of 0.00 million and a net profit of -178.74 million over the latest four quarters. Shareholder's funds are at 590.33 million, and total assets are 622.43 million as of Dec 24.

As of Jun 18, Cullinan Therapeutics, Inc. has a market capitalization of 491.00 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -178.74 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 590.33 million and Total Assets at 622.43 million.

Read More

What does Cullinan Therapeutics, Inc. do?

22-Jun-2025

Cullinan Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $49 million and a market cap of $491 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -32.39%.

Overview: <BR>Cullinan Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -49 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 491.00 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.55 <BR>Return on Equity: -32.39% <BR>Price to Book: 0.89<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Cullinan Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 16, 2022, Cullinan Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor financial metrics and a year-to-date stock performance of -37.77%, significantly underperforming the S&P 500's 2.44% return.

As of 16 May 2022, the valuation grade for Cullinan Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 0.97, an EV to EBIT of -1.12, and a ROCE of -83.79%. <BR><BR>In comparison to its peers, Cullinan Therapeutics has a notably lower valuation profile, with Procaps Group SA being very attractive at a P/E of 605.22, while ARS Pharmaceuticals, Inc. is classified as risky with a P/E of -92.41. The company's recent stock performance has been poor, with a year-to-date return of -37.77%, contrasting sharply with the S&P 500's positive return of 2.44% during the same period, further reinforcing the view that it is overvalued.

Read More

Is Cullinan Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Cullinan Therapeutics, Inc. has a bearish trend with significant weakness indicated by MACD and Bollinger Bands, underperforming the S&P 500 with a year-to-date return of -47.95%.

As of 8 September 2025, the technical trend for Cullinan Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with significant weakness indicated by the MACD and Bollinger Bands on both weekly and monthly time frames. The daily moving averages also confirm a bearish outlook. The RSI shows no signal on the weekly chart but is bullish on the monthly, indicating mixed signals. Dow Theory and OBV are both mildly bearish on the weekly and monthly charts.<BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -47.95% versus the S&P 500's 12.22%, and a one-year return of -63.20% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 404 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.54

stock-summary
Return on Equity

-42.01%

stock-summary
Price to Book

0.82

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-70 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
37.05%
0%
37.05%
6 Months
18.08%
0%
18.08%
1 Year
-17.34%
0%
-17.34%
2 Years
22.17%
0%
22.17%
3 Years
-12.63%
0%
-12.63%
4 Years
-34.73%
0%
-34.73%
5 Years
52800.0%
0%
52800.0%

Cullinan Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Cullinan Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Cullinan Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with significant weakness indicated by the MACD and Bollinger Bands on both weekly and monthly time frames. The daily moving averages also confirm a bearish outlook. The RSI shows no signal on the weekly chart but is bullish on the monthly, indicating mixed signals. Dow Theory and OBV are both mildly bearish on the weekly and monthly charts. In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -47.95% versus the S&P 500's 12.22%, and a one-year return of -63.20% compared to 17.14% for the index....

Read More
Cullinan Therapeutics Hits New 52-Week Low at $5.89

Cullinan Therapeutics Hits New 52-Week Low at $5.89

Cullinan Therapeutics, Inc. has reached a new 52-week low, reflecting a difficult year with a significant stock price decline. The company, with a market capitalization of approximately USD 404 million, is currently operating at a loss and has a price-to-book ratio indicating it is valued below its book value.

Read More
Cullinan Therapeutics Hits New 52-Week Low at $6.24 Amidst Major Decline

Cullinan Therapeutics Hits New 52-Week Low at $6.24 Amidst Major Decline

Cullinan Therapeutics, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, with a market capitalization of approximately USD 404 million, is currently operating at a loss and shows challenging financial metrics, indicating a volatile environment in the biotechnology sector.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-221.77%
EBIT to Interest (avg)
-139.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.55
Sales to Capital Employed (avg)
0.04
Tax Ratio
0.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
2.63%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.97
EV to EBIT
-1.12
EV to EBITDA
-1.12
EV to Capital Employed
0.94
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-83.79%
ROE (Latest)
-32.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 47 Schemes (21.6%)

Foreign Institutions

Held by 80 Foreign Institutions (17.51%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -44.54% vs -1.89% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-75.70",
          "val2": "-54.90",
          "chgp": "-37.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-70.10",
          "val2": "-48.50",
          "chgp": "-44.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.06% vs -242.03% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-196.60",
          "val2": "-190.30",
          "chgp": "-3.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-167.60",
          "val2": "-155.10",
          "chgp": "-8.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-75.70
-54.90
-37.89%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-70.10
-48.50
-44.54%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -44.54% vs -1.89% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-196.60
-190.30
-3.31%
Interest
0.00
0.00
Exceptional Items
0.00
-0.40
100.00%
Consolidate Net Profit
-167.60
-155.10
-8.06%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.06% vs -242.03% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cullinan Therapeutics, Inc. stock-summary
stock-summary
Cullinan Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."